KALA News and Press, Kala Pharmaceuticals Inc. From 03/11/19

Kala Pharmaceuticals (NASDAQ: KALA ): Q4 GAAP EPS of -$0.76 misses by $0.24. More news on: Kala Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

INVELTYS TM launched in January 2019 for the treatment of post-operative inflammation and pain following ocular surgery August 15, 2019 Prescription Drug User Fee Act (PDUFA) target action date for KPI-121 0.25% for the temporary relief of signs and symptoms of dry eye disease ...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that members of its management team will pr...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will report fourth quarter and full...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock option...

Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an...

Kala Pharmaceuticals ( KALA ) is a small-cap biopharma with one product already in the market and one about to have a PDUFA on August 15, 2019. These products are in the ocular disease segment, and while the approved product, INVELTYS, is merely a steroid approved for post-surgical use, the le...

Gainers: ARWR +45% . WSCI +34% . CVM +28% . ABAC +24% . CLDR +23% . SDPI +22% . NBEV +17% . SUPV +17% . AVAV +17% . IMMP +15% . More news on: Arrowhead Pharmaceuticals, WSI Industries Inc., Cel-Sci Corporation, Stocks on the move, , Read more ...

Results from a Phase 3 clinical trial evaluating Bausch Health Companies' ( BHC -1.7% ) loteprednol etabonate ophthalmic gel, 0.38% for the treatment of postoperative pain and inflammation following eye surgery were just published in the Journal of Cataract and Refractive Surgery . ...

NEW YORK, Aug. 31, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Holly Energy Partners, L.P. (NYSE:HEP), First Merchants Corporation (NASD...